Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 15,038 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Vascular Clear all

Conditions: Plasma Cell Myeloma
Interventions: Isatuximab SAR650984, Lenalidomide, Dexamethasone, Montelukast or equivalent, Acetaminophen, Diphenhydramine or equivalent, Methylprednisolone or equivalent; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 337 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2033
U.S. locations: 9
States / cities: Los Angeles, California • Denver, Colorado • Jacksonville, Florida + 6 more

Conditions: Coronary Occlusion
Interventions: coraFlex Catheter, coraForce Catheter, coraCross Catheter; Device
Lead sponsor: ReFlow Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Multiple Myeloma
Interventions: Pembrolizumab, Lenalidomide, Dexamethasone; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years to 99 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Complex Regional Pain Syndromes, Neuralgia, Thoracic Outlet Neurologic Syndrome
Interventions: A2M enriched plasma; Combination Product
Lead sponsor: Neurological Associates of West Los Angeles; Other
Eligibility: 23 Years to 77 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Atherosclerosis, Heart Failure, Congestive, Hypertension, Myocardial Infarction
Interventions: Angiotensin II type 1 receptor antagonists; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Vasospasm, Intracranial, Subarachnoid Hemorrhage
Interventions: Extraventricular Drain, Lumbar Drain; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 110 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease, Severe Hypertriglyceridemia
Interventions: Olezarsen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 21
States / cities: Lincoln, California • Montclair, California • Boca Raton, Florida + 17 more

Conditions: Acute Coronary Syndrome
Interventions: Acetylsalicylic acid, Rivaroxaban, Clopidogrel, Ticagrelor; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 3,037 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 49
States / cities: Alexander City, Alabama • Banning, California • Sylmar, California + 46 more

Conditions: Coronary Disease, Cardiovascular Diseases, Heart Diseases, Neurologic Manifestations
Interventions: Estrogen Replacement Therapy, Surgery; Drug · Procedure
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 55 Years and older · Female only
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Complex Congenital Heart Defect, Dysfunctional RVOT Conduit, Pulmonary Valve Insufficiency, Pulmonary Valve Degeneration
Interventions: SAPIEN 3/SAPIEN 3 Ultra RESILIA THV, SAPIEN 3 THV, SAPIEN 3 Ultra RESILIA THV; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: Not listed
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2031
U.S. locations: 27
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more

Conditions: Multiple Myeloma
Interventions: MFGR1877S; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 11
States / cities: Scottsdale, Arizona • Atlanta, Georgia • Chicago, Illinois + 8 more

Conditions: Chronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia (WM)
Interventions: Shingrix vaccine; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 50 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Stroke, Acute Ischemic Stroke
Interventions: NovaGuide 2 Intelligent Ultrasound System; Device
Lead sponsor: NeuraSignal Inc dba NovaSignal; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Chattanooga, Tennessee

Conditions: Chemotherapy-induced Peripheral Neuropathy
Interventions: Acupuncture, Standard of Care CIPN management; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Cerebrovascular Accident
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Peripheral Arterial Disease, Critical Limb Ischemia
Interventions: Bare Temporary Spur Stent System; Device
Lead sponsor: ReFlow Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 48
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Orange, California + 44 more

Conditions: Coats' Disease, Idiopathic Retinal Telangiectasia, Retinal Angiomatous Proliferation, Polypoidal Choroidal Vasculopathy, Pseudoxanthoma Elasticum, Pathological Myopia, Multi-focal Choroiditis, Rubeosis Iridis, Von Hippel Lindau Disease, BEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL (Disorder)
Interventions: ranibizumab injection (0.5 mg); Drug
Lead sponsor: Manhattan Eye, Ear & Throat Hospital; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: New York, New York

Conditions: Stroke
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Stroke, Stroke, Acute, Cerebrovascular Accident, Cerebrovascular Accident, Acute
Interventions: Ekso gait training, Standard physical therapy; Device · Procedure
Lead sponsor: Sunnyview Rehabilitation Hospital; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Schenectady, New York

Conditions: Stroke
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 45 Years to 65 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Hypertension
Interventions: LCZ696, Olmesartan, LCZ696 matching placebo, Olmesartan matching placebo, amlodipine, hydrochlorothiazide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 60 Years and older
Enrollment: 454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 11
States / cities: Clearwater, Florida • Chicago, Illinois • Baltimore, Maryland + 8 more

Conditions: Acute Coronary Syndrome (ACS)
Interventions: REG1, Heparin; Drug
Lead sponsor: Regado Biosciences, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 26
States / cities: Huntsville, Alabama • Sacramento, California • San Diego, California + 21 more

Conditions: Brain Lesions
Interventions: Contrast; Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Hypertension
Interventions: valsartan and amlodipine; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 728 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Metairie, Louisiana

Search by objective public record fields.

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Single-Arm Study Evaluating Use of the CORA Catheters for the Crossing of Coronary Chronic Total Occlusions

Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)

Forms of Cervical Brachial Syndrome Treated With Plasma Concentrate Enriched for A2M

The Role of Angiotensin Type I Receptor in the Regulation of Human Coronary Vascular Function

Lumbar Drain vs Extraventricular Drain to Prevent Vasospasm in Subarachnoid Hemorrhage

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

Estrogen Replacement to Reduce Risk of Neurologic Injury After Coronary Artery Bypass Graft Surgery

COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction

A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma

Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors

Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke

Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients

Motor Changes Associated With Recovery From Stroke After Therapy

A Prospective Single-Arm Multicenter StuDy of the BarE TEmporary SPur StEnt System foR the tREatment of Vascular Lesions Located in the infrapoplitEal Arteries beLow the Knee (DEEPER REVEAL)

Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy

Brain Electrical Stimulation to Enhance Recovery After Stroke

Achieving Meaningful Clinical Benchmarks With Ekso Gait Training During Acute Stroke Inpatient Rehabilitation.

Sex Differences in Vascular Markers of Stroke Risk

Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension

A Study Assessing the REG1 Anticoagulation System Compared Heparin in Subjects With Acute Coronary Syndrome

DYNA EMBOLIZATION - Pilot Study of IV Dyna CT and CBV Imaging Techniques

The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) Monotherapy